Use of Antifibrotics to Prevent Ventriculoperitoneal Shunt Complications Due to Intra-abdominal Fibrosis: Experimental Study in a Rat Model

J Neurol Surg A Cent Eur Neurosurg. 2015 May;76(3):219-23. doi: 10.1055/s-0034-1389369. Epub 2015 Mar 26.

Abstract

Background: Cerebrospinal fluid shunt operations have reduced the morbidity and mortality of hydrocephalus, but have potential complications. Ventriculoperitoneal (vp) shunt obstruction is one of the common complications of shunt surgery. The obstruction is caused by fibrosis and is usually located on the tip of the ventricular and/or peritoneal catheter.

Objective: In our study, we aimed to demonstrate the known antifibrotic effects of heparin, hyaluronate/carboxymethylcellulose, and icodextrin on peritoneal catheter obstruction in a vp shunt model in rats.

Methods: Thirty-two male Sprague-Dawley rats were used in this study. A shunt catheter was placed in the abdominal cavity. In the control group, isotonic solution, in the study groups, heparin, sodium hyaluronate/carboxymethylcellulose (HA/CMC), and icodextrin were intraperitoneally applied. The severity of adhesions and inflammation around the peritoneal catheter was evaluated after the rats were killed on day 30.

Results: One animal in the heparin group died due to intra-abdominal hemorrhage. We found the most adhesions in the control group. All three drugs (heparin, HA/CMC, icodextrin) were effective for adhesion prevention. HA/CMC was more effective than heparin, and icodextrin was most effective. There was a statistically significant difference between the icodextrin and the control group (p = 0.007).

Conclusion: The intra-abdominal instillation of icodextrin, HA/CMC, and heparin, especially icodextrin, can decrease the rate of vp shunt dysfunction by preventing formation of intraperitoneal fibrosis.

MeSH terms

  • Animals
  • Carboxymethylcellulose Sodium / administration & dosage
  • Carboxymethylcellulose Sodium / pharmacology
  • Dialysis Solutions / administration & dosage
  • Dialysis Solutions / pharmacology
  • Disease Models, Animal
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / pharmacology*
  • Glucans / administration & dosage
  • Glucans / pharmacology
  • Glucose / administration & dosage
  • Glucose / pharmacology
  • Heparin / administration & dosage
  • Heparin / pharmacology
  • Hyaluronic Acid / administration & dosage
  • Hyaluronic Acid / pharmacology
  • Icodextrin
  • Laxatives / administration & dosage
  • Laxatives / pharmacology
  • Male
  • Peritoneal Fibrosis / prevention & control*
  • Rats
  • Rats, Sprague-Dawley
  • Tissue Adhesions / prevention & control*
  • Ventriculoperitoneal Shunt / adverse effects*
  • Viscosupplements / administration & dosage
  • Viscosupplements / pharmacology*

Substances

  • Dialysis Solutions
  • Fibrinolytic Agents
  • Glucans
  • Laxatives
  • Viscosupplements
  • Icodextrin
  • Hyaluronic Acid
  • Heparin
  • Glucose
  • Carboxymethylcellulose Sodium